Insider trade

CEO exercised or converted 6,500 CRL derivative securities

Traded Aug 11, 2026 · Filed Aug 13, 2026

Charles River LaboratoriesCRL

6,500
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 11, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 13, 2026

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001100682-26-000132

Filed / recorded

Aug 13, 2026, 8:37 PM UTC

Added to OQRO

Oct 2, 2026, 12:27 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Issuer CIK

1100682

Ticker

CRL

Reporting person

Birgit Girshick

Relationship

Director, Officer

Officer title

Chief Executive Officer

Security

Stock Options (Right to Buy)

Table

Derivative (Table II)

Transaction date

Aug 11, 2026

Transaction code

M

Shares / units

6,500

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

0

Ownership form

Direct

Amendment

No

Around the same time

6w ago

21KShares · @ $194.12

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record

6w ago

12KShares · @ $208.44

Derivative exercise or conversion — not an open-market buy.

Why it stands out Official record

Director sold ~$10.1M of Charles River Laboratories

Scheduled in advance6w ago